Our hearts go out to those impacted by the recent Hurricanes. If you have had to evacuate and are enrolled in Catalyst Pathways, your medication may be sent to your new location. Please call 1-833-422-8259 to make arrangements. #HurricaneHelene #HurricaneMilton #PatientAccess #RareDisease
Catalyst Pharmaceuticals, Inc.
Pharmaceutical Manufacturing
Coral Gables, Florida 11,718 followers
We are focused on developing and commercializing innovative therapies for people with rare neurological diseases.
About us
About Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
- Website
-
http://www.catalystpharma.com
External link for Catalyst Pharmaceuticals, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Coral Gables, Florida
- Type
- Public Company
- Founded
- 2002
- Specialties
- Neurology, Neuromuscular, Pharmaceuticals, and Rare Disease
Locations
-
Primary
355 Alhambra Circle
Suite 801
Coral Gables, Florida 33134, US
Employees at Catalyst Pharmaceuticals, Inc.
Updates
-
At Catalyst Pharmaceuticals, Inc., our commitment to the community remains steadfast. We extend our heartfelt sympathies to those affected by #HurricaneHelene and are honored to support the American Red Cross in their relief efforts. Together we can make a difference! #HurricaneMilton #SFLRedCross #Helene #DisasterRelief
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
ir.catalystpharma.com
-
Our thoughts are with those impacted by the recent hurricane. With more hurricanes approaching, we wanted to highlight a guide our friends at Epilepsy Alliance Florida developed to help the #Epilepsy Community stay safe and prepared. Download their guide: https://lnkd.in/gr-5rGBh. Epilepsy Alliance America also has several local chapters, if you are having trouble obtaining your medication and need assistance, please reach out to them at https://lnkd.in/gWUrJptn #HurricaneHelene #HurricaneMilton
-
If you are in the #Epilepsy Community and are having trouble obtaining your medication due to the recent hurricanes, please reach out to your local Epilepsy Foundation for assistance: https://lnkd.in/gRvaqAT2 #HurricaneHelene #HurricaneMilton
-
Catalyst team is at World Muscle Society's Annual Meeting #WMS2024 in Prague. Visit stand #4 to connect with us and learn how we are working to support the rare neurological community. https://CatalystPharma.com
-
Are you our new Regional Account Manager (RAM)? Join a collaborative team that is focused on serving our patient communities through effective communication and relationship-building with key external and internal audiences. As our newest RAM serving the Northwest, you will have direct responsibility for representing Catalyst Pharmaceuticals' products to medical professionals who specialize in the treatment of rare neuromuscular conditions. Apply to join our Commercial Team now: https://lnkd.in/g7d8bEDu
Catalyst Pharmaceuticals, Inc - Regional Account Manager-Northwest
recruiting.paylocity.com
-
Catalyst Pharmaceuticals, Inc. is pleased to announce that our partner, DyDo Pharma, Inc., has secured regulatory approval for FIRDAPSE® in Japan. This marks a major step forward in addressing an unmet need for a treatment of LEMS and reinforces FIRDAPSE’s proven effectiveness in improving patient outcomes. >>> Learn more: https://lnkd.in/gyy4RCqx
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
ir.catalystpharma.com
-
Are you at #NMSG24 later this afternoon? Stop by the Mary Duke Ballroom to listen to Dr. Omer Abdul Hamid (Pediatric Neuromuscular Specialist, Nemours Children's Hospital, Orlando, FL) discuss a unique molecular structure of a corticosteroid and its function in Duchenne muscular dystrophy (DMD).
-
Team Catalyst is at Neuromuscular Study Group's 25th Annual Scientific Meeting #NMSG24. Visit our table to learn more about our commitment to raising awareness and providing support to the rare neuromuscular disease community.
-
Did you know that more than half of patients with LEMS received a different diagnosis first? In a study of 241 adult patients, 58% were previously diagnosed with a different condition. Read more on why the road to diagnosis can be so long for patients: https://lnkd.in/gnd7YVjM
Similar pages
Browse jobs
Stock
CPRX
NASDAQ
20 minutes delay
$20.20
0.29 (1.457%)
- Open
- 19.94
- Low
- 19.92
- High
- 20.24
Data from Refinitiv
See more info on